Stephen M Ansell Selected Research

Hodgkin Disease (Hodgkin's Disease)

1/2022	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
1/2022	A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome.
1/2022	Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
1/2022	Current salvage therapies in Hodgkin lymphoma.
12/2021	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
6/2021	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
4/2021	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
1/2021	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
1/2021	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
1/2021	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen M Ansell Research Topics

Disease

92	Neoplasms (Cancer) 05/2022 - 10/2004
82	Lymphoma (Lymphomas) 10/2022 - 02/2004
63	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 06/2002
56	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2002
41	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 08/2005
36	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 04/2006
29	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 02/2022 - 08/2005
21	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 01/2002
14	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 02/2005
12	Disease Progression 01/2020 - 09/2002
10	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2021 - 01/2005
9	Neutropenia 01/2020 - 06/2004
8	Immunoglobulin Light-chain Amyloidosis 01/2020 - 11/2002
8	Multiple Myeloma 01/2018 - 10/2008
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018 - 03/2004
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2018 - 05/2005
7	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2017 - 07/2007
6	Febrile Neutropenia 01/2022 - 12/2013
6	Paraproteinemias (Monoclonal Gammopathy) 01/2019 - 12/2011
6	T-Cell Lymphoma (Lymphoma, T Cell) 10/2016 - 04/2008
6	Thrombocytopenia (Thrombopenia) 02/2016 - 09/2002
5	Fatigue 01/2022 - 10/2009
5	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022 - 05/2015
4	Infections 01/2021 - 06/2009
4	Amyloidosis 01/2020 - 11/2002
4	Autoimmune Diseases (Autoimmune Disease) 10/2019 - 05/2009
3	Leukemia 01/2022 - 07/2012
3	Body Weight (Weight, Body) 01/2021 - 10/2008
2	Obesity 01/2021 - 07/2015
2	Pancreatitis 11/2020 - 09/2020

Drug/Important Bio-Agent (IBA)

33	Rituximab (Mabthera)FDA Link 01/2021 - 01/2002
30	Immunoglobulin M (IgM)IBA 01/2022 - 04/2006
25	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2005
21	Brentuximab VedotinIBA 01/2022 - 01/2011
18	CytokinesIBA 03/2021 - 05/2002
16	NivolumabIBA 01/2022 - 01/2015
15	LigandsIBA 03/2021 - 02/2008
14	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 08/2005
14	Immune Checkpoint InhibitorsIBA 03/2021 - 07/2015
12	Monoclonal AntibodiesIBA 01/2021 - 08/2003
11	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2012
10	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 10/2005
10	Pharmaceutical PreparationsIBA 01/2020 - 09/2002
9	Immunoglobulins (Immunoglobulin)IBA 12/2020 - 04/2006
8	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 01/2018
8	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 01/2018
7	TOR Serine-Threonine KinasesIBA 01/2019 - 08/2005
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2018 - 12/2006
6	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 02/2004
6	Biological ProductsIBA 10/2020 - 02/2008
6	Everolimus FDA Link 10/2018 - 03/2010
5	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 11/2014
5	Chimeric Antigen ReceptorsIBA 01/2022 - 12/2019
5	Lenalidomide (CC 5013)FDA Link 01/2021 - 02/2014
5	RNA (Ribonucleic Acid)IBA 11/2020 - 03/2003
5	ibrutinibIBA 01/2020 - 10/2015
5	Mechanistic Target of Rapamycin Complex 1IBA 10/2018 - 10/2009
5	Dexamethasone (Maxidex)FDA LinkGeneric 08/2018 - 07/2007
5	Interleukin-12 (IL 12)IBA 09/2017 - 01/2002
5	B-Cell Activating FactorIBA 05/2009 - 02/2006
4	axicabtagene ciloleucelIBA 01/2022 - 12/2019
4	Bendamustine Hydrochloride FDA Link 01/2020 - 01/2018
4	AntibodiesIBA 01/2020 - 07/2009
4	Interleukin-2 (IL2)IBA 01/2019 - 07/2009
4	AnthracyclinesIBA 11/2018 - 11/2014
4	Prednisone (Sone)FDA LinkGeneric 03/2016 - 12/2006
4	Vincristine (Oncovin)FDA LinkGeneric 02/2016 - 12/2006
4	Interleukin-10 (Interleukin 10)IBA 01/2016 - 10/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2003
3	varlilumabIBA 12/2020 - 07/2012
3	pembrolizumabIBA 11/2020 - 07/2015
3	Lipase (Acid Lipase)FDA Link 11/2020 - 10/2018
3	Indicators and Reagents (Reagents)IBA 01/2019 - 02/2005
3	Amyloid (Amyloid Fibrils)IBA 01/2019 - 04/2006
3	Programmed Cell Death 1 ReceptorIBA 01/2018 - 01/2016
3	Etoposide (VP 16)FDA LinkGeneric 02/2016 - 07/2007
3	Anaplastic Lymphoma KinaseIBA 09/2015 - 11/2013
3	ibritumomab tiuxetan (Zevalin)FDA Link 07/2013 - 09/2002
3	temsirolimus FDA Link 04/2011 - 08/2005
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 10/2019
2	InterferonsIBA 01/2022 - 09/2012
2	VaccinesIBA 01/2022 - 07/2011
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 01/2018
2	ChromatinIBA 01/2022 - 01/2022
2	Dihydrotachysterol (AT 10)IBA 01/2021 - 10/2019
2	CreatinineIBA 11/2020 - 02/2016

Therapy/Procedure

84	Therapeutics 05/2022 - 09/2002
34	Drug Therapy (Chemotherapy) 01/2022 - 09/2002
21	Immunotherapy 01/2022 - 08/2005
18	Stem Cell Transplantation 10/2022 - 06/2002
10	Hematopoietic Stem Cell Transplantation 10/2022 - 02/2005
7	Radiotherapy 01/2022 - 12/2004
7	Transplantation 01/2022 - 09/2002
6	Salvage Therapy 01/2022 - 01/2015
4	Cell Transplantation 01/2022 - 08/2013
4	Radioimmunotherapy 01/2017 - 09/2002
4	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 04/2006 - 04/2003
3	Drug Tapering 08/2008 - 06/2004
2	Combined Modality Therapy 01/2022 - 11/2015
2	Aftercare (After-Treatment) 01/2022 - 01/2018